The agreement is to generate and optimise antibodies for novel immuno-oncology targets, including access to Iontas' proprietary Mammalian Display technology to select antibodies with optimal biophysical properties.
Iontas' proprietary technology enables the construction of large libraries of stable cell lines displaying human antibodies on their surface.
As well as generating an abundance of therapeutic antibody leads, the technology also addresses "developability" issues early in discovery; increasing the likelihood of successful progress through the development process.
Under the terms of the collaboration, the project provides Adaptate Biotherapeutics with access to Iontas' proprietary Mammalian Display technology, allowing the selection of high affinity antibodies based on their function, stability, expression and developability thereby facilitating a speedy transition through Chemistry, Manufacturing and Controls and eventual manufacturing.
Amneal announces launch of PEMRYDI RTU, a ready-to-use oncology injectable
Medivir and Vetbiolix report positive results from VBX-1000 Proof-of-Concept clinical study
Norgine submits first marketing authorisation application submissions for approval of eflornithine
Innovent Biologics names new Oncology CMO
UroGen's UGN-103 IND accepted by FDA for bladder cancer treatment
Innate Pharma advances Sanofi-developed NK cell engager to Phase 2 for blood cancer patients
Precision Epigenomics partners with TruDiagnostic
Portage Biotech expands evaluation of strategic alternatives
Stamford Pharmaceuticals starts locally advanced basal cell carcinoma (laBCC) trial of SP-002
Candel Therapeutics granted FDA Orphan Drug Designation for CAN-2409 in pancreatic cancer treatment
ELIAS Animal Health names new chief revenue officer
Innate Pharma reports preclinical efficacy of IPH45
Roche attains CE Mark for first companion diagnostic for HER2-low metastatic breast cancer
BioCity Biopharma's BC2027 Phase one study IND application receives US FDA approval